U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21NO3.ClH
Molecular Weight 335.825
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCODONE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]15CCN(C)[C@H](C4)[C@]5([H])CCC2=O

InChI

InChIKey=GCJAEXSZUXBMFS-RNWHKREASA-N
InChI=1S/C18H21NO3.ClH/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1H/t11-,12+,17-,18-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C18H21NO3
Molecular Weight 299.3642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Benzhydrocodone is a prodrug of hydrocodone. Benzhydrocodone is formed by covalently bonding hydrocodone to benzoic acid. Benzhydrocodone itself is not pharmacologically active, but must be metabolized to hydrocodone by enzymes in the intestinal tract to optimally deliver its pharmacologic effects. Hydrocodone is a full agonist of the opioid receptors with a higher affinity for the mu-opioid receptor. Upon binding, hydrocodone produces an analgesic effect with no ceiling. APADAZ a combination of benzhydrocodone and acetaminophen is FDA approved and indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. APADAZ, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death.

CNS Activity

Approval Year

1943
64
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ZOHYDRO ER

Approved Use

ZOHYDRO ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Launch Date

2013
Primary
Approved
8429
APADAZ

Approved Use

APADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen, and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Launch Date

2019
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27138027/
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23.6 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
155 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27138027/
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27138027/
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg multiple, oral (total)
Overdose
Dose: 30 mg
Route: oral
Route: multiple
Dose: 30 mg
Co-administed with::
clarithromycin
valproic acid(250 mg, 2 times per day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: cold
Age Group: 5 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
Other AEs: Adverse event...
Other AEs:
Adverse event (grade 5)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Other AEs: Electrocardiogram QTc interval prolonged...
Other AEs:
Electrocardiogram QTc interval prolonged
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Other AEs: Respiratory depression, Addiction...
Other AEs:
Respiratory depression (grade 5)
Addiction
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Nausea (1%)
Headache (1%)
Dizziness (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
30 mg multiple, oral (total)
Overdose
Dose: 30 mg
Route: oral
Route: multiple
Dose: 30 mg
Co-administed with::
clarithromycin
valproic acid(250 mg, 2 times per day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: cold
Age Group: 5 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
Electrocardiogram QTc interval prolonged
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Withdrawal syndrome neonatal
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Addiction
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Respiratory depression grade 5
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Dizziness 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Headache 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Nausea 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Vomiting 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2B6
664

CYP2C19
991
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2B6
664
 minor
CYP2C19
991
 minor
CYP2D6
1217
 yes
yes (co-administration study)
Comment: The 90% confidence interval (CI) of the geometric means for hydrocodone AUCinf (98 to 115%), AUCt (98 to 115%), and Cmax (93 to 121%) values were within the range of 80 to 125% when a single dose of HYSINGLA ER 20 mg was co-administered with CYP2D6 inhibitor paroxetine
CYP3A4
1737
 yes
yes (co-administration study)
Comment: Co-administration of HYSINGLA ER and CYP3A4 inhibitor ketoconazole increased mean hydrocodone AUC and Cmax by 135% and 78%, respectively;
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5779
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5779
ZINC
ZINC000001280665
http://zinc15.docking.org/substances/ZINC000001280665
eMolecules
29539213
https://www.emolecules.com/cgi-bin/more?vid=29539213
PubMed

PubMed

TitleDatePubMed
[Longitudinal study of parameters of respiratory function tests and blood gas analysis in patients with progressive systemic scleroderma].
2001
Narcotic analgesics for dental pain: available products, strengths, and formulations.
2001 Mar-Apr
[Hospital maternal mortality: causes and consistency between clinical and autopsy diagnosis at the Northeastern Medical Center of the IMSS, Mexico].
2002 Feb
Gateways to clinical trials.
2002 Jul-Aug
Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey.
2002 Jul-Aug
Gender differences in narcotic-induced emesis in the ED.
2002 May
Exacerbation of panic disorder symptoms following Vicodin exposure.
2002 Nov-Dec
Surveillance of drug identification calls: an overlooked poison center responsibility.
2002 Oct
Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant Enterococcus faecium in hospitalized patients.
2002 Oct 15
[Hypoxic brain damage in victims of fatal road traffic accident: prevalence, distribution and association with survival time and other head and extracranial injuries].
2002 Sep
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
2003 Aug
The synergistic analgesic interactions between hydrocodone and ibuprofen.
2003 Dec
Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection.
2003 Feb 25
Trials and tribulations: current challenges in conducting clinical trials.
2003 Jan
Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
2003 Jan
Hair analysis for opiates: evaluation of washing and incubation procedures.
2003 Jun 5
Rapid communication: laparoscopic Anderson-Hynes dismembered pyeloplasty using the da Vinci robot: technical considerations.
2003 Mar
Postmortem oxycodone and hydrocodone blood concentrations.
2003 Mar
Current concepts in acute pain management.
2003 May
[Spanish scientific production in anesthesiology and resuscitation 1983-1995].
2003 Nov
Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study.
2003 Nov
The influence of gender and race on physicians' pain management decisions.
2003 Nov
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.
2003 Nov-Dec
Evaluation of postoperative bupivacaine infusion for pain management after anterior cruciate ligament reconstruction.
2003 Oct
Patterns and trends in opioid use among individuals with back pain in the United States.
2004 Apr 15
1000 office-based hysteroscopies prior to in vitro fertilization: feasibility and findings.
2004 Apr-Jun
Carisoprodol withdrawal syndrome.
2004 Dec
A message of hope.
2004 Fall
Refractory status epilepticus.
2004 Feb
Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
2004 Feb
Postoperative pain management after anterior cruciate ligament reconstruction.
2004 Jan
Loss prevention case of the month. Monitoring remains critical.
2004 Jan
Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone.
2004 Jan-Feb
Dose-response relationship between opioid use and adverse effects after ambulatory surgery.
2004 Jul
Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches.
2004 Jun
Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents.
2004 Jun
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.
2004 Jun
Hallucinations with zolpidem and fluoxetine in an impaired driver.
2004 Mar
CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
2004 Mar
[Detection of thyroid pathology during surgical exploration of the neck for primary hyperthyroidism].
2004 Mar-Apr
[Gender and health in the daily press].
2004 May
Patient-controlled ropivacaine analgesia after arthroscopic subacromial decompression.
2004 May
Topical metronidazole (10 percent) decreases posthemorrhoidectomy pain and improves healing.
2004 May
[Origin and growth of the National Program of Continuous Academic Development for the General Physician].
2004 May-Jun
6-oxo-morphinane oximes: pharmacology, chemistry and analytical application.
2004 Oct
Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs.
2005 Apr 8
Detection of hypoventilation during thoracoscopy: combined cutaneous carbon dioxide tension and oximetry monitoring with a new digital sensor.
2005 Feb
The GC-MS detection and characterization of neopine resulting from opium use and codeine metabolism and its potential as an opiate-product-use marker.
2005 Jun
A 46-year-old man with excruciating shoulder pain.
2005 Mar
Oral analgesics for acute nonspecific pain.
2005 Mar 1
Patents

Patents

04272541
12
07321038
10
08491935
42
08569329
42
JP2000501709A
75
JP2005506351A
26
JP2010163446A
20
JP2010509227A
64
JP2011511782A
10
JP2011520977A
49
JP2013241461A
10
JP4806507B2
10

Sample Use Guides

In Vivo Use Guide
APADAZ Immediate-release tablets: 6.12 mg benzhydrocodone (equivalent to 6.67 mg benzhydrocodone hydrochloride) and 325 mg acetaminophen. Initiate treatment with APADAZ at 1 or 2 tablets every 4 to 6 hours as needed for pain. Dosage should not exceed 12 tablets in a 24­ hour period.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:49:25 GMT 2023
Edited
by admin
on Fri Dec 15 17:49:25 GMT 2023
Record UNII
QKZ0920OV3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCODONE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
HYDROCODONE HYDROCHLORIDE [MI]
Common Name English
NSC-35549
Code English
Hydrocodone hydrochloride [WHO-DD]
Common Name English
7,8-DIHYDROCODEINONE HYDROCHLORIDE
Common Name English
NSC-117856
Code English
HYDROCODONE HYDROCHLORIDE [MART.]
Common Name English
DIHYDROCODEINONE HYDROCHLORIDE
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3-METHOXY-17-METHYL-, HYDROCHLORIDE (1:1), (5.ALPHA.)-
Common Name English
MORPHINAN-6-ONE, 4,5.ALPHA.-EPOXY-3-METHOXY-17-METHYL-, HYDROCHLORIDE
Systematic Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3-METHOXY-17-METHYL-, HYDROCHLORIDE, (5.ALPHA.)-
Systematic Name English
HYDROCODONE HCL
Common Name English
Code System Code Type Description
NSC
117856
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
SMS_ID
100000077616
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
PUBCHEM
12358607
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
DRUG BANK
DBSALT002210
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
RXCUI
236931
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY RxNorm
CAS
25968-91-6
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
EVMPD
SUB14131MIG
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
ECHA (EC/EINECS)
247-382-7
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
FDA UNII
QKZ0920OV3
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
NSC
35549
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID80180632
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY
MERCK INDEX
m6093
Created by admin on Fri Dec 15 17:49:26 GMT 2023 , Edited by admin on Fri Dec 15 17:49:26 GMT 2023
PRIMARY Merck Index
Related Record Type Details
Structure of HYDROCODONE
PARENT -> SALT/SOLVATE
Structure of HYDROCODONE HYDROCHLORIDE DIHYDRATE
SOLVATE->ANHYDROUS
Structure of HYDROCODONE HYDROCHLORIDE MONOHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of HYDROCODONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966